COMBINATION OF RADIONUCLIDE 177LU-PSMA THERAPY WITH PEMBROLIZUMAB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP

Carleen Cullinane, Kelly Waldeck, Laura Kirby, Buck E Rogers, Peter Eu, Richard W Tothill, Rodney J Hicks

2020-06-23

Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients with somatostatin receptor-2 (SSTR2)-ex..